Long-term safety and efficacy evaluation of lunsekimig in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who completed a previous lunsekimig CRSwNP study

Trial Identifier: LTS18300
Sponsor: Sanofi
Start Date: May 2025
Primary Completion Date: January 2031
Study Completion Date: January 2031
Condition: Nose and Sinus Disorder

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ARGENTINA, Buenos Aires Buenos Aires, ARGENTINA, 1121
ARGENTINA, Mendoza Mendoza, ARGENTINA, 5500
ARGENTINA, Santa Fe Rosario, Santa Fe, ARGENTINA, 2000
BELGIUM Gent, BELGIUM, 9000
BELGIUM Leuven, BELGIUM, 3000
BULGARIA Sofia, BULGARIA, 1612
POLAND, Dolnoslaskie Wroclaw, Dolnoslaskie, POLAND, 50-750
POLAND, Malopolskie Kraków, Malopolskie, POLAND, 30-033
POLAND, Mazowieckie Warsaw, Mazowieckie, POLAND, 00-909
POLAND, Slaskie Katowice, Slaskie, POLAND, 40-611
POLAND, Wielkopolskie Poznan, Wielkopolskie, POLAND, 60-693
UNITED KINGDOM, Manchester MANCHESTER, Manchester, UNITED KINGDOM, M13 9WL
UNITED KINGDOM, Newcastle upon Tyne Newcastle Upon Tyne, Newcastle upon Tyne, UNITED KINGDOM, NE7 7DN
UNITED STATES, California La Jolla, California, UNITED STATES, 92037
UNITED STATES, Idaho Boise, Idaho, UNITED STATES, 83706
UNITED STATES, Oklahoma Tulsa, Oklahoma, UNITED STATES, 74137
UNITED STATES, Texas Bellaire, Texas, UNITED STATES, 77401
UNITED STATES, Texas Dallas, Texas, UNITED STATES, 75231
UNITED STATES, Texas Mckinney, Texas, UNITED STATES, 75070
UNITED STATES, Texas San Antonio, Texas, UNITED STATES, 78258